You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 10, 2024

Claims for Patent: 9,833,523

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,833,523

Title:	Pharmacokinetic determination of intravitreal agents
Abstract:	Compositions and methods for evaluating a pharmacokinetic property of an ophthalmic agent administered by intravitreal injection are provided.
Inventor(s):	Christoforidis; John B. (Columbus, OH), Knopp; Michael V. (Columbus, OH)
Assignee:	The Ohio State University (Columbus, OH)
Application Number:	13/868,453
Patent Claims:	1. A method for evaluating a pharmacokinetic property of an intravitreally placed anti-vascular endothelial growth factor (VEGF) agent, comprising a) administering a composition comprising the anti-VEGF agent Bevacizumab or Ranibizumab radiolabeled with iodine-124(.sup.124I) into the vitreous cavity of the eye of a subject, b) serially imaging the eye of the subject to detect positron emission levels in the vitreous cavity of the eye by positron emission tomography-computed tomography (PET-CT), and c) calculating a pharmacokinetic property of the ophthalmic agent from the positron emission levels measured in step b), wherein the pharmacokinetic property is selected from the group consisting of clearance pattern and intravitreal half-life. 2. The method of claim 1, wherein the subject has been diagnosed with age-related macular degeneration (AMD).

Details for Patent 9,833,523

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2032-04-24
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006	⤷ Try a Trial	2032-04-24
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012	⤷ Try a Trial	2032-04-24
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016	⤷ Try a Trial	2032-04-24
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018	⤷ Try a Trial	2032-04-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.